Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring

Procyk, Grzegorz; Klimczak-Tomaniak, Dominika; Sygitowicz, Grażyna; Tomaniak, Mariusz

doi:10.3390/jcm11071763

Cited by 13 publications

(14 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[36][37][38][39] Finally, different antiplatelet therapies have been shown to influence the expression of miRs, which may possibly help to explain some of the variations seen when comparing patient cohorts. 13,40 We found no association between the candidate miRs and platelet maturity markers. In a previous study from our group, immature platelet markers were increased in STEMI patients from blood samples obtained upon arrival.…”

Section: Discussionmentioning

confidence: 63%

See 1 more Smart Citation

Platelet Function and Maturity and Related microRNA Expression in Whole Blood in Patients with ST-Segment Elevation Myocardial Infarction

Pedersen,

Hvas,

Pasalic

et al. 2023

Thromb Haemost

View full text Add to dashboard Cite

Background Reduced effect of antiplatelet therapy has been reported in patients with ST-segment elevation myocardial infarction (STEMI). MicroRNAs (miRs) may influence platelet function and maturity, and subsequently the effect of antiplatelet therapy. Objectives We aimed to explore the association between miR expression and platelet function and maturity in patients with acute STEMI and healthy individuals. Methods We performed an observational study of STEMI patients admitted directly to primary percutaneous coronary intervention. Patients were treated with antiplatelet therapy according to guidelines. Within 24 hours after admission, blood samples were obtained to measure: the expression of 10 candidate miRs, platelet function markers using advanced flow cytometry, platelet aggregation, serum thromboxane B2, and platelet maturity markers. Furthermore, blood samples from healthy individuals were obtained to determine the normal variation. Results In total, 61 STEMI patients and 50 healthy individuals were included. STEMI patients had higher expression of miR-21–5p, miR-26b-5p, and miR-223–3p and lower expression of miR-150–5p, miR423–5p, and miR-1180–3p than healthy individuals. In STEMI patients, the expression of miR-26b-5p showed the most consistent association with platelet function (all p-values <0.05, Spearman's rho ranging from 0.27 to 0.41), while the expression of miR-150–5p and miR-223–3p showed negative associations with platelet function. No association between miR expression and platelet maturity markers was observed. Conclusion In patients with STEMI, the expression of six miRs was significantly different from healthy individuals. The expression of miR-26b-5p may affect platelet function in acute STEMI patients and potentially influence the effect of antiplatelet therapy.

show abstract

Section: Discussionmentioning

confidence: 63%

“…36 37 38 39 Finally, different antiplatelet therapies have been shown to influence the expression of miRs, which may possibly help to explain some of the variations seen when comparing patient cohorts. 13 40…”

Section: Discussionmentioning

confidence: 99%

Platelet Function and Maturity and Related microRNA Expression in Whole Blood in Patients with ST-Segment Elevation Myocardial Infarction

Pedersen,

Hvas,

Pasalic

et al. 2023

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…Since PCI with stent implantation requires the usage of dual antiplatelet treatment (DAPT) for a prolonged period of time, it is associated with an increased risk of bleeding, particularly in elderly patients who also use anticoagulants for atrial arrhythmia [97]. MicroRNAs associated with platelet aggregation could be used as biomarkers of platelet response to DAPT treatment (Table III) [98][99][100]. Due to the limited value of platelet reactivity tests, this may offer a practical approach [75,98].…”

Section: Platelet Response To Dual Antiplatelet Treatmentmentioning

confidence: 99%

“…MicroRNAs associated with platelet aggregation could be used as biomarkers of platelet response to DAPT treatment (Table III) [98][99][100]. Due to the limited value of platelet reactivity tests, this may offer a practical approach [75,98]. MicroRNA-driven dosages of antiplatelet agents could enable personalization of antiplatelet treatment to prevent episodes of excessive bleeding or stent thrombosis [98][99][100].…”

Section: Platelet Response To Dual Antiplatelet Treatmentmentioning

confidence: 99%

“…Due to the limited value of platelet reactivity tests, this may offer a practical approach [75,98]. MicroRNA-driven dosages of antiplatelet agents could enable personalization of antiplatelet treatment to prevent episodes of excessive bleeding or stent thrombosis [98][99][100]. High platelet reactivity during treatment is associated with decreased expression levels of circulating miR-233 [99].…”

Section: Platelet Response To Dual Antiplatelet Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Cardiac microRNAs: diagnostic and therapeutic potential

Kabłak-Ziembicka,

Badacz,

Okarski

et al. 2023

Arch Med Sci

View full text Add to dashboard Cite

MicroRNAs are small non-coding post-translational biomolecules which, when expressed, modify their target genes. It is estimated that microRNAs regulate production of approximately 60% of all human proteins and enzymes that are responsible for major physiological processes. In cardiovascular disease pathophysiology, there are several cells that produce microRNAs, including endothelial cells, vascular smooth muscle cells, macrophages, platelets, and cardiomyocytes. There is a constant crosstalk between microRNAs derived from various cell sources. Atherosclerosis initiation and progression are driven by many pro-inflammatory and pro-thrombotic microRNAs. Atherosclerotic plaque rupture is the leading cause of cardiovascular death resulting from acute coronary syndrome (ACS) and leads to cardiac remodeling and fibrosis following ACS. MicroRNAs are powerful modulators of plaque progression and transformation into a vulnerable state, which can eventually lead to plaque rupture. There is a growing body of evidence which demonstrates that following ACS, microRNAs might inhibit fibroblast proliferation and scarring, as well as harmful apoptosis of cardiomyocytes, and stimulate fibroblast reprogramming into induced cardiac progenitor cells. In this review, we focus on the role of cardiomyocyte-derived and cardiac fibroblast-derived microRNAs that are involved in the regulation of genes associated with cardiomyocyte and fibroblast function and in atherosclerosis-related cardiac ischemia. Understanding their mechanisms may lead to the development of microRNA cocktails that can potentially be used in regenerative cardiology.

show abstract

The Role of MicroRNA in Migraine: A Systemic Literature Review

2023

View full text Add to dashboard Cite

Migraine is a common primary headache disorder, affecting about 14% of the population. Importantly, it was indicated as the second cause of disability globally and the leading cause among young women. Despite the widespread prevalence, migraine remains underdiagnosed and undertreated. The possible solution may be microRNAs—small, non-coding molecules. Until now, multiple studies have shown the great value of microRNA in both the diagnosis and treatment of different human diseases. Furthermore, a significant role in neurological disorders has been suggested. Little research regarding the utility of microRNA in migraine has been conducted, however, the results so far appear to be promising. We performed an electronic article search through PubMed and Embase Database to further explore the topic. After the analysis, according to PRISMA 2020 guidelines, we included 21 studies. The dysregulation was observed in migraine in general, as well as in different types and phases; thus, miRNAs emerge as promising diagnostic biomarkers. Additionally, some studies showed the influence of the intervention with miRNA levels on neuroinflammation and the expression of peptides, which are crucial in migraine pathogenesis. This review aims to summarize the current knowledge about the role of miRNAs in migraine and encourage to further research in this field.Kindly check and confirm the edit made in the title.I checked and confirm. Graphical Abstract

show abstract

Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring

Cited by 13 publications

References 71 publications

Platelet Function and Maturity and Related microRNA Expression in Whole Blood in Patients with ST-Segment Elevation Myocardial Infarction

Platelet Function and Maturity and Related microRNA Expression in Whole Blood in Patients with ST-Segment Elevation Myocardial Infarction

Cardiac microRNAs: diagnostic and therapeutic potential

The Role of MicroRNA in Migraine: A Systemic Literature Review

Contact Info

Product

Resources

About